a) | ||||
2017 | Dispensed a benzodiazepine or z-hypnotic | |||
N = 3764 | ||||
cOR | p-value | aOR (95% CI) | p-value | |
Age | ||||
- ≤ 25 | 1.0 (ref.) | 1.0 (ref.) | ||
- 26-35 | 1.0 | .80 | 0.9 (0.6–1.4) | .76 |
- 36-45 | 1.0 | .85 | 1.0 (0.7–1.5) | .94 |
- 46-55 | 1.6 | .02 | 1.7 (1.1–2.5) | .05 |
- ≥ 56 | 1.9 | < .01 | 1.2 (1.1–1.3) | .01 |
Gender | ||||
- Men | 1.0 (ref.) | 1.0 (ref.) | ||
- Women | 1.2 | < .01 | 1.2 (1.1–1.3) | < .01 |
The number of dispensations of OAT opioids | ||||
- ≥ 52 | 1.0 (ref.) | 1.0 (ref.) | ||
- 13-51 | 1.3 | < .01 | 1.2 (1.1–1.5) | .01 |
- 7-12 | 1.1 | .27 | 1.0 (0.9–1.3) | .73 |
- 1-6 | 1.3 | .03 | 1.1 (0.9–1.4) | .23 |
OAT opioidsa | ||||
- Buprenorphine (incl. combinations) | 1.0 (ref.) | 1.0 (ref.) | ||
- Methadone (incl. Levomethadone) | 1.4 | < .01 | 1.3 (1.2–1.4) | < .01 |
Dispensed a non-OAT opioid | 3.5 | < .01 | 3.0 (2.6–3.5) | < .01 |
Dispensed a gabapentinoid | 3.0 | < .01 | 2.5 (2.1–3.0) | < .01 |
b) | ||||
2017 | Dispensed a gabapentinoid | |||
N = 845 | ||||
cOR | p-value | aOR (95% CI) | p-value | |
Age | ||||
- ≤ 25 | 1.0 (ref.) | 1.0 (ref.) | ||
- 26-35 | 1.1 | .71 | 1.2 (0.6–2.2) | .60 |
- 36-45 | 1.0 | .90 | 1.1 (0.6–2.0) | .79 |
- 46-55 | 1.0 | .99 | 0.9 (0.5–1.7) | .75 |
- ≥ 56 | 1.0 | .95 | 0.8 (0.4–1.5) | .45 |
Gender | ||||
- Men | 1.0 (ref.) | 1.0 (ref.) | ||
- Women | 1.3 | < .01 | 1.1 (1.0–1.3) | .16 |
The number of dispensations of OAT opioids | ||||
- ≥ 52 | 1.0 (ref.) | 1.0 (ref.) | ||
- 13-51 | 0.9 | .62 | 0.9 (0.7–1.1) | .31 |
- 7-12 | 1.0 | .95 | 0.9 (0.7–1.3) | .72 |
- 1-6 | 1.5 | .01 | 1.2 (0.9–1.7) | .26 |
OAT opioidsa | ||||
- Buprenorphine (incl. combinations) | 1.0 (ref.) | 1.0 (ref.) | ||
- Methadone (incl. Levomethadone) | 1.1 | .46 | 1.1 (0.9–1.3) | .41 |
Dispensed a non-OAT opioid | 3.7 | < .01 | 3.0 (2.5–3.5) | <.01 |
Dispensed a benzodiazepine or z-hypnotic | 3.0 | < .01 | 2.5 (2.1–3.0) | <.01 |